|
KMID : 1030220190200020063
|
|
Journal of Korean Diabetes
2019 Volume.20 No. 2 p.63 ~ p.66
|
|
|
Saxendaⓡ Frenzy: Opinions of an Endocrine and Metabolism Specialist
|
|
Kim Sung-Rae
|
|
|
Abstract
|
|
|
|
Globally, the problem of obesity is increasing, and the prevalence of obesity in Korea is also rising rapidly. Obesity is a risk factor for cardiometabolic diseases including type 2 diabetes mellitus, hypertension, cardiovascular disease, and some types of cancer. Therefore, prevention of various metabolic diseases or symptom relief through effective treatment of obesity is a very important problem. According to the obesity guidelines of the Obesity Society of Korea in 2018, obesity medication is recommended for patients with a body mass index (BMI) of 30 kg/m2 or more or a BMI of 27 kg/m2 or more, and one or more obesity accompanying diseases (type 2 diabetes, hypertension, dyslipidemia). In this case, it is recommended that the basic treatment for obesity (diet, exercise, and behavior therapy) should be performed in parallel with Saxendaⓡ treatment. The glucagon-like peptide 1 analogue, Saxendaⓡ, has been validated as a long-term effective and safe treatment for obesity, and is expected to be a promising drug for the treatment of obesity and the prevention of pre-diabetes in the future. However, in Korea, where non-standard obesity treatments are widely practiced, it is necessary to improve the health of obese patients by being treated with Saxendaⓡ along with diet, exercise and behavior therapy.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, type 2, Glucagon-like peptide 1, Metabolic diseases, Obesity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|